Support of Strawman Solution and Limited Preventative Registration proposals

[Bruce W Longbottom <longbottom_bruce@xxxxxxxxx>]

To Whom It May Concern,

Please note that Eli Lilly and Company supports adoption of both the "Strawman 
Solution" and the "Limited Preventative Registration" proposals in order to 
enhance our ability to protect our trademarks when used as or in domain names 
in new gTLDs.  In particular we support the Limited Preventative Registration 
proposal as a cost-efficient and streamlined method to register names across 
hundreds of new registries as opposed to the current mechanism.

Our company is the applicant for the .LILLY gTLD (Application number 
1-1018-57217).  Since 2004, we (or one of our affiliates) have filed 97 UDRP 
proceedings covering 446 domains with respect to our trademarks.  We have also 
sent cease and desist letters which have resulted in the successful transfer of 
25 domains.  In total, we have successfully obtained 471 domains containing our 
trademarks registered and used in bad faith by third parties.  Our vigilance 
has been fueled by our concern about the misleading and potentially harmful use 
of our trademarks in the domain names of websites, especially in light of the 
proliferation of illegal online drug sellers and the obvious risk to consumer 
and patient safety.  While we understand that these proposals may not eliminate 
the bad faith use and registration of domains incorporating our marks, we 
believe these proposals will provide cost effective assistance to Lilly and 
other trademark owners to help manage what we anticipate will be an explosion 
of cybersquatting with the introduction of the new gLTDs.

Thank you for your consideration.  Please let me know if you have any questions.

Bruce Longbottom
Assistant General Counsel
Trademarks, Copyrights and Information Technology
Eli Lilly and Company
phone: (317) 651-1346
fax: (317) 276-1919
email: longbottom_bruce@xxxxxxxxx

CONFIDENTIALITY NOTICE: This email message (including all attachments) is for 
the sole use of the intended recipient(s) and may contain confidential and 
privileged information.  Any unauthorized review, use, disclosure, copying or 
distribution is strictly prohibited. If you are not the intended recipient, 
please contact the sender by reply email and destroy all copies of the original 
message.